Ritodrine HCL for the prevention of premature labor in twin pregnancies.
The perinatal mortality rate for twin gestation is in the range of 15%, and this is due predominantly to prematurity, although twins may also be born growth retarded. Ritodrine HCl, a beta sympathomimetic drug, has been shown to be effective, both in stopping premature labor and in preventing intrauterine growth retardation. With this in mind, a double-blind study using ritodrine HCl or placebo was begun in order to study its effect on premature labor, intrauterine growth retardation, and the perinatal mortality rate in twins. Thus far, 30 patients have delivered and have been followed to 6 weeks postpartum. Although the results on individual patients have remained blinded to the investigators, an initial evaluation of the ritodrine and placebo groups have revealed no difference with respect to gestational age, birth weight, or perinatal mortality. These preliminary results are not significant. However, it appears that ritodrine HCl is a safe oral agent for the antepartum gravida and her fetus. The study will be continued until approximately 100 patients have been enrolled.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D011272:Pregnancy, Multiple; D011412:Propanolamines / Q000627:therapeutic use*; D012312:Ritodrine / Q000627:therapeutic use*; D014427:Twins; D014428:Twins, Conjoined / Q000175:diagnosis; D014463:Ultrasonography
D011412:Propanolamines; D012312:Ritodrine